21 July 2022 12:50Ziccum AB and Zurich University of Applied Sciences apply for joint funding on 3D modelling project of unique drying technology for thermostable vaccines
Ziccum AB, in partnership with the prestigious Zurich University of Applied Sciences, is applying for funding to Eurostars for a joint project developing the 3D modelling of LaminarPace, its unique room-temperature drying system that formulates vaccines...
Ziccum has chosen TEKCELEO, an innovative mechatronic manufacturer with advanced knowledge of nebulizers, for the development of its new nebulizer. The component is central to the advanced drying capabilities and scaleup of Ziccum’s LaminarPace...
29 June 2022 11:30Three key learnings as collaboration between Ziccum and Emerging Virus Unit at Aix-Marseille University draws to a close
In Ziccum’s recent major strategy renewal it sharpened its focus onto three key vaccine platforms and streamlined its R&D projects down to three key partnerships. The company is also pleased to now conclude its long-term collaboration with the...
22 June 2022 08:30Ziccum installs new cell lab enabling in-house in vitro research
Lund, June 22, 2022 —Ziccum AB (publ) (‘Ziccum’) has completed the installation of a new cell lab, on schedule, as part of its strategy of intensive technology development. The new cell lab increases the company’s capabilities...
17 June 2022 09:00From vision to action: new Ziccum CEO update
On May 9, 2022, Ann Gidner became new CEO of Ziccum, hitting the ground running with a raft of new strategies that included targeting three key high-potential vaccines, streamlining the company’s project pipeline and strengthening the focus on industrial...
3 June 2022 10:45Ziccum further extends evaluation agreement with leading pharmaceutical corporation
Lund, June 3, 2022 —Ziccum AB (publ) (‘Ziccum’) has extended an ongoing pilot evaluation study agreement with a leading pharmaceutical corporation following the completion of the latest stage of the project. Ziccum will ship the dry-formulated...
Ziccum’s Director of Development Anna Lönn has now been elected onto the Technical Activities Committee of the US National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), which will have its first meeting on May 23, 2022...
The Board of Ziccum AB has decided to officially change the company’s language to English for all external market communications as from Friday May 6 2022. Key factors in the decision are that Ziccum has an extensive network of international stakeholders...
6 May 2022 12:30Ziccum AB ändrar språk för informationsgivning till engelska
Styrelsen för Ziccum AB har beslutat att ändra bolagets språk till engelska för all extern marknadskommunikation från och med fredagen den 6 maj 2022. Viktiga faktorer bakom beslutet är att Ziccum har ett omfattande nätverk...
28 April 2022 11:06Kommuniké från årsstämma i Ziccum AB (publ)
Ziccum AB (publ) (”Ziccum”) avhöll den 28 april årsstämma i Lund. Vid stämman fattades bland annat följande beslut. Fastställande av årsbokslut och ansvarsfrihet Stämman beslutade att fastställa...
28 April 2022 08:55ZICCUM AB (publ) Interim report Q1 2022
INTERIM REPORT Q1 2022: 1 JANUARY - 31 MARCH 2022 To read the digital Report click here: https://reports-en.ziccum.com/interim-report-q1-2022/ Q1 2022 Significant events during Q1 (Jan-March) At the Extraordinary General Meeting held on January 18, in...
28 April 2022 08:55ZICCUM AB (publ) Delårsrapport Q1 2022
DELÅRSRAPPORT Q1: 1 JANUARI - 31 MARS 2022 För att läsa hela rapporten digitalt, klicka här: https://reports.ziccum.com/delarsrapport-q1-2022/ Q1 2022 Väsentliga händelser Q1 (jan-mars) På den extra bolagsstämma...
27 April 2022 14:55ZICCUM AB: key targeted technology developments underpin new strategic focus
Select key technology developments will underpin Ziccum’s new strategic focus of generating further data in three vaccine platforms, including mRNA/LNP, so strengthening its position as an attractive industrial partner. The key technology developments...
27 April 2022 14:55ZICCUM AB: utvalda projekt i fokus för Ziccums teknikutveckling
För att stödja ambitionen att generera ytterligare data inom tre utvalda vaccinplattformar, inkluderande mRNA/LNP, och för att förstärka positionen som en attraktiv partner för industrin kommer fokus för Ziccums tekniska...
26 April 2022 13:00ZICCUM AB expands lab facilities and mRNA/LNP capabilities with strategic investments
Ziccum AB has significantly expanded its lab facilities and capabilities, particularly in the area of mRNA/LNP. Strategic investments include a new cell lab and a system for manufacturing and evaluating dry formulations of mRNA/LNP materials. Chairman...
26 April 2022 13:00ZICCUM AB utökar labbfaciliteter och mRNA/LNP-kapacitet med strategiska investeringar
Ziccum AB har utökat sina labbfaciliteter och kapacitet att generera data inom området mRNA/LNP. Dessa strategiska investeringar inkluderar ett nytt cell-laboratorium och ett system för tillverkning och utvärdering av torra formuleringar...
25 April 2022 14:00ZICCUM AB sharpens focus on three key vaccine platforms
In a strategic sharpening of its focus Ziccum AB is targeting three key vaccine planforms in its research and development work through 2022 and 2023 – driven by input from external collaborations and new internal technology capabilities. Ziccum...
25 April 2022 14:00ZICCUM AB fokuserar på tre viktiga vaccinplattformar
Efter en strategisk översyn fokuserar Ziccum på tre viktiga vaccinplattformer i sitt forsknings- och utvecklingsarbete under 2022 och 2023 – drivet av information från externa samarbeten och nya interna resurser. Ziccums ordförande...
Tillträdande VD, Ann Gidner och Styrelsens ledamöter Andreas Pettersson samt Kristian Kierkegaard har köpt aktier i Ziccum AB. Ann Gidner, som tillträder sin position som VD den 9 maj har under perioden 29 mars – 1 april köpt...
28 March 2022 08:33ZICCUM AB appoints Ann Gidner as new CEO – ‘outstanding record in business development and leadership speaks for itself’, Chairman
Ann Gidner takes office as new CEO of Ziccum AB on May 9, 2022. Ann has extensive CEO and Business Development experience, driving growth in a wide range of early-stage life science companies. In a global career spanning 25+ years she has held senior...